| Literature DB >> 28115102 |
Yishu Yan1, Yang Ji2, Nan Su3, Xiang Mei4, Yi Wang5, Shanshan Du6, Wenming Zhu7, Chong Zhang8, Yuan Lu9, Xin-Hui Xing10.
Abstract
Low molecular weight heparins (LMWHs) are produced by chemical or enzymatic depolymerization of unfractionated heparin (UFH). Besides their well-known anticoagulant effects, LMWHs have also been reported to exhibit numerous anti-inflammatory properties. Previous studies have, however, shown that different production processes result in unique structural characteristics of LMWHs. The structural variations may help explain the different therapeutic spectrums in disease treatment for non-anticoagulant effects. In the present review, we summarize major advances in understanding and exploiting the anti-inflammatory disorder activities of LMWHs, based on mechanistic studies, preclinical experiments and clinical trials. We highlight differences in these activities of commercially available LMWHs produced using different manufacturing processes. We stress the importance of structure-activity relationship (SAR) studies on the non-anticoagulant effects of LMWHs and discuss strategies for exploring new clinical indications.Entities:
Keywords: Heparin; Inflammation; Low molecular weight heparins; Non-anticoagulant
Mesh:
Substances:
Year: 2016 PMID: 28115102 DOI: 10.1016/j.carbpol.2016.12.037
Source DB: PubMed Journal: Carbohydr Polym ISSN: 0144-8617 Impact factor: 9.381